Welcome to our dedicated page for Vtv Therapeutics SEC filings (Ticker: VTVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The vTv Therapeutics Inc. (VTVT) SEC filings page on Stock Titan provides access to the company’s official disclosures as a Nasdaq-listed issuer of Class A common stock. vTv Therapeutics is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases, with a clinical pipeline led by cadisegliatin (TTP399), a liver-selective glucokinase activator in Phase 3 development for type 1 diabetes.
Through this page, users can review current and historical filings submitted to the U.S. Securities and Exchange Commission, including Forms 8‑K that detail material events. Recent 8‑K filings describe quarterly financial results, private placement transactions involving common stock and warrants, and participation in investor conferences. For example, vTv Therapeutics has filed 8‑Ks outlining an approximately $80 million private placement of Class A common shares and pre-funded warrants, along with accompanying warrants, and has disclosed registration rights agreements for the resale of these securities.
Investors interested in vTv Therapeutics’ development of cadisegliatin and other small molecules can use this filings page to locate quarterly and annual reports (Forms 10‑Q and 10‑K when available), which typically summarize research and development spending, cash position, and risk factors associated with drug development. The page also surfaces current reports on material events (Form 8‑K), which may include updates on financing arrangements, clinical milestones, and other significant corporate actions.
Stock Titan complements the raw SEC documents with AI-powered summaries designed to highlight key points from lengthy filings, helping readers quickly understand topics such as capital structure changes, contract liabilities, warrant terms, and the financial context for ongoing clinical trials. Users can also track filings that relate to equity issuances and warrants, which are important for understanding potential dilution and funding of the cadisegliatin program.
By reviewing vTv Therapeutics’ SEC filings in one place, investors and researchers can follow how the company reports its financial condition, capital-raising activities, and material developments tied to its late-stage diabetes-focused pipeline.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, led by cadisegliatin, a potential first-in-class liver-selective glucokinase activator in a Phase 3 trial. The FDA removed a clinical hold on the cadisegliatin program on March 14, 2025, the company reinitiated patient screening in May 2025, randomized the first participant on August 6, 2025, and shortened the CATT1 study from 12 to 6 months; top-line data are expected in the second half of 2026. The U.S. Patent Office allowed claims for a crystalline salt form of cadisegliatin in August 2025.
On the balance sheet as of June 30, 2025, vTv held $25.9 million in cash, had an accumulated deficit of $310.9 million, and reported a six-month net loss attributable to common shareholders of $11.1 million. There was no product revenue in H1 2025 (prior period included $1.0 million of collaboration revenue in H1 2024). The company completed a $51.0 million private placement in February 2024 and has an ATM program; however, management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing.
vTv Therapeutics Inc. filed a current report to note that it issued a press release on August 12, 2025 announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for the detailed results.
The company also lists an exhibit for the cover page interactive data file, which is embedded within the Inline XBRL document. The report clarifies that the financial information furnished, including the press release, is not deemed "filed" for liability purposes under the Exchange Act unless specifically incorporated into another filing.